These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Yoon HH; Shi Q; Sukov WR; Wiktor AE; Khan M; Sattler CA; Grothey A; Wu TT; Diasio RB; Jenkins RB; Sinicrope FA Clin Cancer Res; 2012 Jan; 18(2):546-54. PubMed ID: 22252257 [TBL] [Abstract][Full Text] [Related]
5. HER2 status in gastric/gastro-oesophageal junctional cancers: should determination of gene amplification by SISH use HER2 copy number or HER2: CEP17 ratio? Kumarasinghe MP; de Boer WB; Khor TS; Ooi EM; Jene N; Jayasinghe S; Fox SB Pathology; 2014 Apr; 46(3):184-7. PubMed ID: 24614718 [TBL] [Abstract][Full Text] [Related]
6. Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival. Thompson SK; Sullivan TR; Davies R; Ruszkiewicz AR Ann Surg Oncol; 2011 Jul; 18(7):2010-7. PubMed ID: 21267790 [TBL] [Abstract][Full Text] [Related]
7. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer. He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643 [TBL] [Abstract][Full Text] [Related]
8. HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma. Hu Y; Bandla S; Godfrey TE; Tan D; Luketich JD; Pennathur A; Qiu X; Hicks DG; Peters JH; Zhou Z Mod Pathol; 2011 Jul; 24(7):899-907. PubMed ID: 21460800 [TBL] [Abstract][Full Text] [Related]
9. Alterations of the CCND1 and HER-2/neu (ERBB2) proteins in esophageal and gastric cancers. Bizari L; Borim AA; Leite KR; Gonçalves Fde T; Cury PM; Tajara EH; Silva AE Cancer Genet Cytogenet; 2006 Feb; 165(1):41-50. PubMed ID: 16490596 [TBL] [Abstract][Full Text] [Related]
10. EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer. Fichter CD; Timme S; Braun JA; Gudernatsch V; Schöpflin A; Bogatyreva L; Geddert H; Faller G; Klimstra D; Tang L; Hauschke D; Werner M; Lassmann S Int J Cancer; 2014 Oct; 135(7):1517-30. PubMed ID: 24510732 [TBL] [Abstract][Full Text] [Related]
11. HER2 expression in oesophageal carcinoma and Barrett's oesophagus associated adenocarcinoma: An Australian study. Nagaraja V; Shaw N; Morey AL; Cox MR; Eslick GD Eur J Surg Oncol; 2016 Jan; 42(1):140-8. PubMed ID: 26422587 [TBL] [Abstract][Full Text] [Related]
13. Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3. Ross JS; Fakih M; Ali SM; Elvin JA; Schrock AB; Suh J; Vergilio JA; Ramkissoon S; Severson E; Daniel S; Fabrizio D; Frampton G; Sun J; Miller VA; Stephens PJ; Gay LM Cancer; 2018 Apr; 124(7):1358-1373. PubMed ID: 29338072 [TBL] [Abstract][Full Text] [Related]
14. HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations. Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Uehara T; Fujimoto M; Tsuruyama T; Date H; Haga H Lung Cancer; 2014 Sep; 85(3):373-8. PubMed ID: 25047676 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry. Sato-Kuwabara Y; Neves JI; Fregnani JH; Sallum RA; Soares FA BMC Cancer; 2009 Jan; 9():6. PubMed ID: 19128465 [TBL] [Abstract][Full Text] [Related]
16. HER2 Gene Amplification by Fluorescence In Situ Hybridization (FISH) Compared With Immunohistochemistry (IHC) in 122 Equivocal Gastric Cancer Cases. Liu X; Wang X; Wang B; Ren G; Ding W Appl Immunohistochem Mol Morphol; 2016 Aug; 24(7):459-64. PubMed ID: 26317310 [TBL] [Abstract][Full Text] [Related]
17. In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancer. Spears M; Taylor KJ; Munro AF; Cunningham CA; Mallon EA; Twelves CJ; Cameron DA; Thomas J; Bartlett JM Breast Cancer Res Treat; 2012 Apr; 132(2):463-70. PubMed ID: 21638049 [TBL] [Abstract][Full Text] [Related]
18. The significance of the HER-2 status in esophageal adenocarcinoma for survival: an immunohistochemical and an in situ hybridization study. Prins MJ; Ruurda JP; van Diest PJ; van Hillegersberg R; Ten Kate FJ Ann Oncol; 2013 May; 24(5):1290-7. PubMed ID: 23334118 [TBL] [Abstract][Full Text] [Related]
19. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization. Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of the HER2 amplification status in oesophageal adenocarcinoma by conventional and automated FISH: a tissue microarray study. Prins MJ; Ruurda JP; van Diest PJ; van Hillegersberg R; ten Kate FJ J Clin Pathol; 2014 Jan; 67(1):26-32. PubMed ID: 24043715 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]